The role of natural killer cells in chronic myeloid leukemia

The role of natural killer cells in chronic myeloid leukemia

Chronic myeloid leukemia is a neoplasia resulting from a translocation between chromosomes 9 and 22 producing the BCR-ABL hybrid known as the Philadelphia chromosome (Ph). In chronic myeloid leukemia a proliferation of malignant myeloid cells occurs in the bone marrow due to excessive tyrosine kinas...

Full description

Bibliographic Details
Main Authors:	Anna Carolyna Araújo Danier, Ricardo Pereira de Melo, Marcelo Henrique Napimoga, Maria Theresa Cerávolo Laguna-Abreu
Format:	Article
Language:	English
Published:	Elsevier 2011-06-01
Series:	Revista Brasileira de Hematologia e Hemoterapia
Subjects:	Leukemia, myelogenous, chronic, BCR-ABL Positive Killer cells, natural killer cell lectin-like receptor subfamily D Protein kinase inhibitors
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300015

Similar Items

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice
by: Antonio Almeida, et al.
Published: (2019-08-01)

Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia
by: Begoña San José Ruiz, et al.
Published: (2015-01-01)

Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
by: Maria Juracy Petrola, et al.
Published: (2012-01-01)

Chronic myeloid leukemia: past, present, future
by: Patricia Weinschenker Bollmann, et al.
Published: (2011-06-01)

Isolated monocytosis was the flag preceding abnormalities in other parameters of complete blood counts in chronic myeloid leukemia with e1a2 (minor, P190) chimeric transcripts
by: Jae Won Yun, et al.
Published: (2019-03-01)

Leukemia Inhibitory Factor Suppresses NKG2D mRNA Expression and Presentation on Human Natural Killer Cells
by: Zahra Abdoli, et al.
Published: (2021-02-01)

Trends in mortality of adult patients diagnosed with myeloid leukemia from 1994 to 2011 in southeastern Brazil
by: Fernando Callera, et al.
Published: (2015-02-01)

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response
by: Melissa Pereira Machado, et al.
Published: (2011-06-01)

Several different cytogenetic clones arising during treatment of Philadelphia positive chronic myeloid leukemia with tyrosine kinase inhibitors lead to the progression into Philadelphia negative acute myeloid leukemia
by: Denčić-Fekete Marija, et al.
Published: (2021-01-01)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
by: Xiaoying Lan, et al.
Published: (2016-11-01)

Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy
by: Stamatović Dragana, et al.
Published: (2012-01-01)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
by: Peng Zeng, et al.
Published: (2020-09-01)

Diversity of breakpoints of variant Philadelphia chromosomes in chronic myeloid leukemia in Brazilian patients
by: Maria de Lourdes Lopes Ferrari Chauffaille, et al.
Published: (2015-02-01)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
by: Roberta Bitencourt, et al.
Published: (2011-12-01)

Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib
by: Ćojbašić Irena, et al.
Published: (2011-01-01)

The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era
by: Ilana Zalcberg Renault, et al.
Published: (2011-12-01)

Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis
by: Poonam P Jain, et al.
Published: (2012-01-01)

Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome
by: Daiana Landenberger de Carvalho, et al.
Published: (2012-01-01)

Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital
by: Samuel Roosevelt Campos dos Reis, et al.
Published: (2013-06-01)

Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia
by: Vlad Andrei Cianga, et al.
Published: (2021-04-01)

NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia
by: Ming-Chin Chang, et al.
Published: (2019-01-01)

Leucemia mieloide crónica, estado del arte Myeloid cronic leukemia, state of the art
by: Luz Aída Rey, et al.
Published: (2009-08-01)

Patients' perceptions about diagnosis and treatment of chronic myeloid leukemia: a cross-sectional study among Brazilian patients
by: Nelson Hamerschlak, et al.

Perfil do estresse oxidativo em pacientes portadores de Leucemia MielÃide CrÃnica
by: Maria Juracy Solon Petrola
Published: (2011)

Chronic myelogenous leukemia on target
by: Veronika Némethová, et al.
Published: (2018-07-01)

Chronic Myeloid Leukemia with b3a3 (e14a3) Fusion: A Rare BCR/ABL Rearrangement Presenting with Thrombocytosis – Does MTHFR Polymorphism Matter
by: Mohammad Muhsin Chisti, et al.
Published: (2018-07-01)

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission
by: Pierre‐Yves Dumas, et al.
Published: (2019-09-01)

Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia
by: Takero Shindo, et al.
Published: (2021-04-01)

Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis
by: Hélène Haguet, et al.
Published: (2020-05-01)

Detection of p190BCR-ABL AND p210BCR-ABL fusion transcripts in patients with chronic myeloid leukemia (CML) using qualitative RT-PCR
by: Aya Bonilla, Carlos Alberto, et al.
Published: (2014-10-01)

Use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML)
by: C. B. Almeida, et al.
Published: (2016-11-01)

The More, The Better: “Do the Right Thing” For Natural Killer Immunotherapy in Acute Myeloid Leukemia
by: Sarah Parisi, et al.
Published: (2017-10-01)

Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
by: Mousa Vatanmakanian, et al.
Published: (2019-04-01)

In Vitro Culture with Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients
by: Beatriz Sanchez-Correa, et al.
Published: (2017-08-01)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
by: Gabriel Etienne, et al.
Published: (2019-09-01)

Análisis de costo-efectividad de nilotinib, dasatinib e imatinib como terapia de primera línea en leucemia mieloide crónica en Colombia, 2012
by: Martín Romero, et al.
Published: (2014-03-01)

Deep and early molecular response induced by nilotinb in a newly diagnosed patient with chronic myeloid leukemia (CML)
by: Antonella Russo Rossi
Published: (2015-10-01)

Transcripto BCR-ABL atípico en un paciente con leucemia mieloide crónica Atypical BCR-ABL transcript in a patient with chronic myeloid leukemia
by: Ana María Amor Vigil, et al.
Published: (2011-09-01)

New insights into antigen specific immunotherapy for chronic myeloid leukemia
by: Li Yangqiu, et al.
Published: (2012-12-01)

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy
by: Huang X, et al.
Published: (2019-06-01)